Education
About Us
Working with TipRanks
Follow Us
Co-Diagnostics Inc (CODX)
NASDAQ:CODX
CODX Stock Chart & Stats
$0.37
-$0.07(-8.42%)
At close: 4:00 PM EST
$0.37
-$0.07(-8.42%)
Day’s Range― - ―
52-Week Range$0.23 - $1.55
Previous CloseN/A
Volume146.43K
Average Volume (3M)10.09M
Market Cap
$22.57M
Enterprise Value-$2.38M
Total Cash (Recent Filing)$11.44M
Total Debt (Recent Filing)$1.47M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Mar 19, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding60,892,582
10 Day Avg. Volume1,334,715
30 Day Avg. Volume10,088,102
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.42
Price to Sales (P/S)5.81
P/FCF Ratio-0.76
Enterprise Value/Market Cap-0.11
Enterprise Value/Revenue-4.69
Enterprise Value/Gross Profit-13.78
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$1.50Price Target Upside305.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe Indian market presents significant opportunities for Co-Diagnostics through the CoSara joint venture, with potential for 30,000 MTB test placements at primary health centers.
Product InnovationCo-Diagnostics' PCR Pro is a desktop RT-PCR device that offers diagnostic performance comparable to higher-priced devices but at a significantly lower cost.
Strategic PartnershipsCo-Diagnostics has signed an agreement with Arabian Eagle Manufacturing to commercialize Co-Dx technologies across Saudi Arabia and 18 MENA nations.
Bears Say
Capital RequirementsThe company may need to raise additional capital at the current price level, which could impact shareholder value.
Market Success UncertaintyThe company faces risks related to the potential failure to achieve commercial success with its products.
Regulatory RisksThere are risks associated with the potential failure to secure regulatory clearance for Co-Diagnostics' clinical evaluations.
Co-Diagnostics News
CODX FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was $0.23 and its highest was $1.55 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is $22.57M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Mar 19, 2026 which is in 107 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Nov 13, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.03.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -0.12.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 60,892,582 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -10.811%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in CODX
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
CODX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the company's strategic initiatives and international expansion efforts as major drivers of future growth. However, significant financial challenges remain, with declining revenue and continued net losses, albeit with improved operational efficiency.View all CODX earnings summariesCODX Stock 12 Month Forecast
Average Price Target
$1.50
▲(305.41% Upside)
Technical Analysis
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Ownership Overview
3.33% Insiders
3.30% Mutual Funds
2.24% Other Institutional Investors
88.58% Public Companies and
Individual Investors